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AbstrACt
Introduction Self-management interventions show 
promising results on symptom outcomes and self-
management behaviours. The Symptom Navi© 
Programme (SN©P) is a nurse-led intervention supporting 
patients’ symptom self-management during anticancer 
treatment. It consists of written patient information 
(Symptom Navi© Flyers (SN©Flyers)), semistructured 
consultations and a training manual for nurses.
Methods and analysis This pilot study will evaluate 
the implementation of the SN©P based on the Reach 
Effectiveness—Adoption Implementation Maintenance 
framework at Swiss outpatient cancer centres. We will 
use a cluster-randomised design and randomise the nine 
participating centres to the intervention or usual care group. 
We expect to include 140 adult cancer patients receiving 
first-line systemic anticancer treatment. Trained nurses at the 
intervention clusters will provide at least two semistructured 
consultations with the involvement of SN©Flyers. Outcomes 
include patients’ accrual and retention rates, patient-reported 
interference of symptoms with daily functions, symptom 
burden, perceived self-efficacy, quality of nursing care, 
nurse-reported facilitators and barriers of adopting the 
programme, nurses’ fidelity of providing the intervention 
as intended, and patients’ safety (patients timely reporting 
of severe symptoms). We will use validated questionnaires 
for patient-reported outcomes, focus group interviews with 
nurses and individual interviews with oncologists. Linear 
mixed models will be used to analyse patient-reported 
outcomes. Focus group and individual interviews will be 
analysed by thematic analysis.
Ethics and dissemination The Symptom Navi© Pilot 
Study has been reviewed and approved by Swiss Ethic 
Committee Bern (KEK-BE: 2017–00020). Results of the 
study will be disseminated in peer-reviewed journal and at 
scientific conferences.
trial registration number NCT03649984; Pre-results.
IntroduCtIon
Anticancer treatments are increasingly 
provided in the outpatient setting.1 2 Cancer 
outpatients report substantial symptom 
burden related to disease and side effects of 
anticancer treatments.3 4 Symptom intensity 
usually increases between treatment applica-
tions,5 when patients are at home and health-
care providers are not immediately available. 
Cancer patients report unmet supportive 
care needs to learn how to self-manage their 
symptoms.6 
Symptom self-management is a dynamic 
process of integrating adequate behaviours 
and strategies to prevent, relieve or decrease 
symptoms.7 This process includes symptom 
and treatment management, dealing with 
the emotional and physical consequences 
of disease and treatment, and adapting 
strengths and limitations of this study
 ► One strength of the study protocol is its integration 
in a larger research and development programme: 
after several steps of development and content val-
idation of the Symptom Navi© Programme (SN©P), 
we now conduct a pilot implementation study in-
cluding the evaluation of preliminary effectiveness 
of the SN©P.
 ► This pilot study explores the implementation of the 
SN©P based on the Reach Effectiveness—Adoption 
Implementation Maintenance framework.
 ► We apply a cluster-randomised design with nine 
Swiss outpatient cancer centres allocated to the 
implementation of the SN©P or usual care comple-
mented with qualitative methods.
 ► We assess patient-reported outcomes over 16 
weeks to explore effect sizes for calculating the 
sample size for a full powered cluster randomised 
controlled trial (RCT).
 ► Long-term impact and maintenance of the SN©P 
are not included in this pilot study and will need fur-
ther investigation.
 o
n
 16 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-027942 on 9 July 2019. Downloaded from 
2 Bana M, et al. BMJ Open 2019;9:e027942. doi:10.1136/bmjopen-2018-027942
Open access 
life roles.8 9 Self-management behaviours are based on 
several core competencies including problem solving, 
decision-making, communication with healthcare profes-
sionals, tailoring recommendations to the individual situ-
ation and taking action.10–12 There are two core elements 
of self-management interventions that are most frequently 
applied: (1) tailoring the content of the intervention to 
patient’s needs and (2) facilitating patient’s self-efficacy 
by using goal setting and action planning.13
Self-efficacy is a subjective belief that a person can 
achieve a planned task or action, even if it becomes chal-
lenging.14 Fostering patient self-efficacy is a pivotal core 
element because of its impact on patient self-management 
behaviours.13 15 Self-efficacy is a mediator for a persons’ 
ability to acquire self-management behaviours10 14 and to 
manage symptoms.9 12 Therefore, supporting self-efficacy 
might play a key role for self-management interventions 
and successful self-management behaviours.
It is still unclear what combination of core elements 
makes a self-management intervention effective13 because 
the format, content and outcomes of the investigated 
interventions are very heterogeneous.13 16–19 The hetero-
geneity of intervention and outcomes preclude meta-anal-
yses in systematic reviews and this has led to mainly 
narrative syntheses.13 18–21 Frequently reported effects of 
self-management interventions were decreased symptom 
intensity or burden (eg, fatigue, depression, anxiety, 
distress),13 17 18 21–24 increased quality of life,13 17 22 23 better 
physical functioning19 or performance,18 and improved 
self-efficacy.17 18 20 21 However, two systematic reviews 
reported ambiguous effects on quality of life20 24 and 
self-efficacy.24 Further research should clarify whether 
the intervention’s content was ineffective, or whether 
contextual factors (eg, nurses’ workload) prevented the 
intended effects.
Important aspects of interventions supporting self-man-
agement remain scarcely investigated. A majority of 
recently published systematic reviews focused on self-man-
agement interventions during survivorship or the rehabil-
itation phase of cancer patients,16 17 19 21 22 24 and a minority 
on interventions during active treatment phase.20 23 25 
Studies rarely included a description of how to support 
patients in communicating their symptoms and asking 
for support when needed,26 or at what moment they have 
to make contact the care team if a symptom becomes 
severe.27 Trained healthcare professionals who work 
collaboratively within a multidisciplinary team should 
provide support and guidance about care seeking.13 15 In 
most studies, healthcare professionals other than nurses 
provided the interventions for supporting self-manage-
ment.20 23 24
Nurses are in close contact with cancer patients and 
should play a key role in supporting symptom self-man-
agement.6 28 29 In a randomised controlled trial, a 
nurse-led intervention for cancer patients during 
chemotherapy was associated with decreased patient-re-
ported problems,29 and showed reduced symptom 
intensity/burden, improved self-efficacy and enhanced 
self-management behaviours.30 However, nurse-led inter-
ventions supporting symptom self-management are chal-
lenging and complex because they require a structured 
but flexible behaviour of nurses in tailoring the inter-
vention to individual situations.15 31 32 Implementation of 
such complex interventions should include a thorough 
analysis of contextual factors (eg, organisational read-
iness for change, workload) and take into account the 
resources needed to apply the intervention.33 34
In 2011, nurses from a Swiss hospital initiated the 
Symptom Navi© Programme (SN©P) for patients during 
anticancer treatments to address the need of cancer 
patients asking for more information about symptom 
management.35 36 The SN©P has received attention from 
other Swiss cancer centres who are interested to imple-
ment this programme.
Aim and objectives
The overall aim of this study is to evaluate the implemen-
tation of the SN©P at Swiss outpatient cancer centres 
and to explore its preliminary effectiveness compared 
with usual care. Implementation of newly developed 
interventions depend on organisational structures and 
the collaboration of involved stakeholders.37 Therefore, 
we based the evaluation of the implementation process 
on the Reach Effectiveness—Adoption Implementation 
Maintenance (RE-AIM) framework.38–40 This five-dimen-
sion framework considers outcomes on individual and 
organisational level. The maintenance dimension cannot 
be addressed in a pilot study.
Patients’ perceived self-efficacy is associated with 
self-management behaviour, symptom outcomes and 
daily functioning.41 The primary objective is to explore 
the impact of the SN©P on patients’ symptom interfer-
ence with their daily functions (affective and activity) 
compared with usual care.
Secondary objectives are to:
1. Assess accrual and retention rates of patients (reach).
2. Investigate the impact of the SN©P on patient symp-
tom severity and burden, and their self-efficacy (effec-
tiveness).
3. Explore barriers and facilitators (eg, work-related fac-
tors, available resources) of adopting the SN©P in the 
outpatient cancer centres (adoption).
4. Explore nurses’ fidelity to the SN©P training manual 
within daily routines, and estimate needed resources 
to implement the SN©P (implementation).
5. Explore patients’ evaluation on nurses’ support for 
symptom management (implementation).
MEthods And AnAlysIs
design
We will apply a cluster-randomised design with two parallel 
arms complemented with qualitative methods. The unit 
of randomisation is the participating outpatient cancer 
centre with each centre representing a cluster. A clus-
ter-randomised design was chosen to avoid contamination 
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between the intervention and control groups.42 Clus-
ter-randomised trials need thorough sample and cluster 
size estimations,43 which are based on assumptions about 
the relevant effect size, recruitment potential and intra-
cluster correlation; because reliable information on these 
parameters is not available, we decided to conduct a pilot 
study based on a sufficient but feasible sample size. We will 
use this pilot study to estimate effect sizes and sample size 
needed for future studies, and to monitor patient safety.44 
For the evaluation of the RE-AIM dimensions reach and 
effectiveness, we will mainly apply quantitative methods; for 
the dimensions adoption and implementation, we will use 
qualitative methods.
setting and eligibility criteria
The study will take place at nine outpatient cancer 
centres in the German-speaking parts of Switzerland. 
Cancer centres providing systemic outpatient anticancer 
treatments (chemotherapy, targeted therapy, immuno-
therapy- and hormonal therapy) will be eligible. We will 
exclude outpatient cancer centres where a former version 
of the SN©P is already implemented. Eligibility criteria 
for patients are listed in table 1.
Registered and regularly employed nurses who have 
worked for at least 1 year in cancer care will provide 
the SN©P. Physicians with at least 1 year experience in 
oncology will be involved to assess the acceptance of the 
SN©P at an institutional level.
Intervention: sn©P
The SN©P is a nurse-led intervention to facilitate 
cancer patients’ symptom self-management including 
semistructured consultations with the involvement of 
symptom-specific information leaflets (Symptom Navi© 
Flyers (SN©Flyers)). We outlined in the nurse-training 
manual the delivery of the consultation and the use of 
flyers. The development of the SN©P was guided by 
patient education principles considered effective in 
patients with chronic health conditions, such as building 
partnership with patients, focusing on patients’ needs11 45 
and self-management strategies.9 10 12 The development, 
content and evaluation of the SN©P are detailed in a 
separate manuscript (Bana et al, in preparation).
Symptom Navi© Flyers
SN©Flyers are written leaflets about 16 commonly occur-
ring symptoms that patients may experience with anti-
cancer treatments (table 2). Each SN©Flyer describes 
one symptom, guides patients to rate the severity of the 
symptom (mild, moderate, severe) and provides easy 
understandable evidence-based recommendations for 
symptom relief and management. If a patient perceives 
a symptom to be severe, they are asked to immediately 
contact the treating outpatient centre. During the devel-
opment phase of the SN©Flyers, the contents were eval-
uated by 48 healthcare professionals and patients using 
the Item Content Validity Index (I-CVI)46 achieving an 
excellent I-CVI of 0.9.47 In addition, 10 cancer patients 
who used the SN©Flyers, confirmed the utility of the 
recommendations for self-management and the benefit 
of semistructured nurse-led consultations, assessed with 
semistructured interviews.48
Semistructured nurse-led consultations
Nurses will provide two semistructured consultations with 
all patients starting a first-line systemic anticancer treat-
ment, tailored to the patient’s treatment protocol and 
expected side effects. These consultations are structured 
along six key elements: (1) preparing the semistructured 
consultation and choosing relevant SN©Flyers, (2) evalu-
ating patient’s willingness and motivation for a consulta-
tion, (3) providing information on common side effects 
with the SN©Flyers, (4) introducing symptom self-man-
agement, (5) facilitating symptom self-management and 
(6) documenting the consultation.49 Patient’s willingness 
will be assessed by asking his consent for the consultation. 
The interpretation of patient’s motivation will be based 
on the active participation and being attentive during the 
conversation. Nurses will have to structure the key elements 
according to patient’s needs, often leading to circular and 
iterative conversation sequences.11 12 While the first semi-
structured consultation will focus on explaining expected 
side effects and how to use the SN©Flyers at home, all 
following consultations will explicitly focus on a patient’s 
individual situation and needs. Nurses may provide addi-
tional written information as available at their centres and 
will decide on whether or not further consultations are 
needed. The SN©P is an intervention that aims to stimu-
late patient’s self-management of symptoms and comple-
ments usual care, which mainly focuses on information 
provision. Differences between centres regarding infor-
mation provision might be a bias. To reduce this bias, we 
will record all additional information material delivered 
at each centre and report them descriptively (brochures, 
leaflets). Motivational interviewing techniques (resisting 
Table 1 Eligibility criteria for patients
Inclusion criteria Exclusion criteria
 ► 18 years and older.
 ► Newly diagnosed with any early or advanced/metastatic 
cancer disease within 15 weeks of providing informed 
consent.
 ► Scheduled for a first-line anticancer treatment.
 ► Insufficiently literate in German.
 ► Diagnosed with a recurrence of cancer disease.
 ► Solely treated by surgical and radiation therapy.
 ► Receiving complementary care by a professional palliative 
care team.
 ► Already participating in another psychosocial study.
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the ‘righting reflex’, understanding patient’s motivation, 
listening with empathy and empowering the patient) will 
be used to enable patient’s active participation during 
the conversation, to support patient’s self-efficacy and to 
facilitate behavioural changes, if needed.50 Patients will 
be invited to ask for additional SN©Flyers if they desire 
more information.
Training for nurses
The two trainers are members of the research team that 
developed the training courses, hold a master degree 
in nursing science and are senior lecturers. Nurses will 
be trained with two standardised training courses (in 
total 6 hours of training) based on a training manual 
that has been face validated by a steering committee 
including two clinical experts for oncology nursing, a 
nursing manager and two researchers. Details about the 
content of the trainings are described in table 3. Between 
the initial and the follow-up training, nurses will prac-
tise semistructured consultations using the SN©Flyers 
according to the initial training and the training manual. 
Table 2 Available SN©Flyers and timing of semistructured nurse-led consultations
Available SN©Flyers Timing of semistructured nurse-led consultations
Leaflets for symptom self-management:
 ► Alopecia.
 ► Anxiety.
 ► Breathlessness.
 ► Diarrhoea.
 ► Emesis and nausea.
 ► Fatigue.
 ► Increased susceptibility: infections and bleeding.
 ► Irradiated skin.
 ► Loss of appetite.
 ► Inflamed oral mucosa.
 ► Obstipation.
 ► Pain.
 ► Peripheral neuropathy.
 ► Sexuality.
 ► Skin alteration: feet and hand.
 ► Skin alterations related to target therapies.
First semistructured consultation:
All patients will be provided with the leaflets "General information 
onSN©Flyers" and "list of all available SN©Flyers", and 
approximately three symptom-specific SN©Flyers based on most 
expected side effects in line with planned treatment protocol; this 
consultation takes place during the first treatment application at 
the outpatient cancer centre.
Second semistructured consultation:
Patients will be provided with complementary SN©Flyers based 
on their experienced symptoms and needs. This consultation 
takes place during the second treatment application at the 
outpatient cancer centre.
Complementary leaflets: 
 ►  Complementary interventions to reduce pain. 
 ►  General information on SN©Flyers. 
 ►  Information on oxaliplatin. 
 ►  List of all available SN©Flyers. 
 ►  Pain relieve by medication. 
 ►  Support at home (useful addresses). 
SN©Flyers, Symptom Navi© Flyers.
Table 3 Objectives and content of SN©P training courses
Training and duration Objective Content
Initial training: about 4 hours Introduce SN©P  ► Self-efficacy.
 ► Symptom self-management.
 ► Nurse–patient communication.
 ► Strategies for selecting appropriate SN©Flyers.
 ► How to conduct semistructured consultations 
according to the six key elements*.
 ► Motivational interviewing techniques.
Follow-up training: about 2 hours Reinforce acquired knowledge/skills Answering nurses’ questions regarding their 
experience with providing the semistructured 
consultations embedded in discussions and role 
plays
*Six key elements: (1) preparing the semistructured consultation and choosing relevant SN©Flyers, (2) evaluating patient’s willingness 
and motivation for a consultation, (3) providing information on common side effects with the SN©Flyers, (4) introducing symptom self-
management, (5) facilitating symptom self-management and (6) documenting the consultation.
 SN©Flyers, Symptom Navi© Flyers (written information leaflets for patients).
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Additionally, nurses will receive a handbook and pocket 
cards to facilitate the implementation of semistructured 
consultations within their daily routines. Pocket cards 
provide nurses with concrete examples how to guide 
the communication during the consultations based on 
motivational interviewing techniques. Nurses will use the 
pocket cards during consultations. The follow-up training 
will address nurses’ experience with the SN©P, as well 
as questions and potential challenges that might have 
occurred during the semistructured consultations.
Control: usual nursing care supporting self-management of 
symptoms
Nurses at the control centres will provide symptom 
management support according to their usual practice. 
This generally includes providing oral information about 
expected side effects of treatments, handing out written 
information as available at the centre (eg, pharmaceu-
tical and Swiss Cancer League brochures) and getting in 
touch with patients by phone calls, if needed.
outcomes
Outcomes will be based on the RE-AIM framework and 
represent individual and organisational levels. We will assess 
patient accrual and retention rates (reach); evaluate the 
impact of the SN©P on patient-reported outcomes (effective-
ness); explore barriers and facilitators at participating centres 
to deliver the intervention (adoption); evaluate nurses’ fidelity 
to the training manual in routine clinical practice and 
patients’ evaluation on nurses’ support for symptom manage-
ment (implementation).38 Outcomes addressing effectiveness 
will be based on the theory of symptom self-management 
(TSSM).7 51 The TSSM addresses five patient-related dimen-
sions: (1) perceived self-efficacy, (2) current symptoms, (3) 
symptom self-management behaviours, (4) demographic 
and psychosocial characteristics and (5) functional status 
(performance outcomes). This framework considers self-ef-
ficacy as a mediator between symptom intensity and patients’ 
functional status. An overview of used instruments to assess 
patient-reported outcomes are provided in table 4, and an 
overview of all study outcomes, data collection methods and 
assessment schedule are provided in table 5.
Reach
Patients’ characteristic data will include medical (age, 
gender, diagnosis, co-morbidities, pharmaceutical infor-
mation of treatment and Karnovsky index) and socio-
demographic information (mother tongue, housing 
context, highest education degree). Accrual and reten-
tion rates of patients’ participation in the study will be 
obtained by recruitment logs completed at each site.
Effectiveness
The main outcome of interest will be the mean change in 
symptom interference with daily functions from baseline 
(BL) (ie, before treatment starts) to 16 weeks after BL. The 
rationale for the primary outcome is based on a previous 
study using the TSSM reporting that patients’ functional 
performance increased after nurse-led interventions on 
symptom self-management support.51 Number and type of 
experienced symptoms depend on cancer type and treat-
ment.52 We therefore chose a period of 16 weeks assuming 
Table 4 Instruments used to assess patient-reported outcomes
Instruments
(RE-AIM dimension) Outcomes Scale Validity/reliability
MDASI
(effectiveness)
13 items on symptoms, 
and 6 items on symptom 
interference with daily 
functions
11-point Likert-scale, 
0=not present and 10=as bad 
as you can imagine
Developed for cancer setting
German version: Cronbach alpha 
0.82 (symptom intensity) and 0.84 
(interference)54
SES6G
(effectiveness)
6 items on patient’s perceived 
self-efficacy
10-point Likert-scale, 1=not at 
all confident and 10=totally 
confident
Developed for chronic conditions, 
applied in cancer settings
German version: construct validity 
r=0.578, p<0.001; internal consistency: 
Crohnbach alpha 0.9355
LASA Mood Scale
(effectiveness)
1-item: emotional well-being Visual Analogue Scale 
(100 mm), 0=happy
100=miserable
Concurrent validity between LASA 
Mood Scale and a comprehensive 
28-item adjective checklist (original in 
German: Befindlichkeitsskala BfS) was 
acceptable (median r=0.6, p<0.001) 
with breast cancer patients, and 
has proven to be valid for emotional 
distress screening72
PR-CISE
(implementation)
5 items on patient’s 
experience of nurse-led 
supportive care
Yes; somewhat; no Developed for chemotherapy setting28; 
translation of items into German for 
study: validation has to be confirmed
LASA, linear analogue self-assessment; MDASI, MD Anderson Symptom Inventory; PR-CISE, patient-reported chemotherapy indicators 
of symptoms and experiences; RE-AIM, Reach Effectiveness—Adoption Implementation Maintenance; SES6G, self-efficacy for managing 
chronic disease.
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that most patients are still under treatment. We also assume 
that the SN©P might affect patient’s estimation on symptom 
interference over this period, because patient’s positive atti-
tude for self-management has been shown to be associated 
with increased physical, emotional and functional well-being 
over 6 months.53 Other outcomes will include mean changes 
in symptom intensity, perceived self-efficacy and quality of 
nursing care assessed four times over a period of 16 weeks. 
The following outcomes to assess effectiveness will be used:
 ► Symptoms severity, their interference with daily 
functioning and symptom burden will be assessed 
by the validated German version of the MD Anderson 
Symptom Inventory (MDASI).54 The MDASI contains 
two dimensions: (1) the severity of thirteen common 
symptoms and (2) the interference of these symp-
toms with daily function on an activity and an affective 
subdimension. The dimensions symptom severity and 
symptom interference summarise an overall symptom 
burden score.
 ► Perceived self-efficacy will be assessed with the vali-
dated German version of the Self-Efficacy for Managing 
Chronic Disease Scale (SES6G).55 We added an item 
asking, ‘how confident do you feel that you can 
manage your symptoms to be able to do things you 
would like to do?’ This general question on perceived 
self-efficacy complements the more specific items of 
the SES6G (eg, self-efficacy for managing fatigue or 
pain).
Depressive moods might affect a person’s belief to 
accomplish a desired behaviour or to achieve a target 
outcome (self-efficacy).56 To control for the emotional 
state of the patients, we added a one-item Visual Analogue 
Scale on mood asking ‘how do you rate your mood during 
the last two weeks?’.57
Table 5 Overview of assessed outcomes based on RE-AIM framework
RE-AIM dimensions
(Level of evaluation) Outcomes Data collection methods Assessment schedule
Reach
(Individual)
Patients’ characteristics, accrual and 
retention rates
Medical records, recruitment 
logs at each centre
Study start: patients’ 
recruitment and enrolment
Effectiveness
(Individual)
Symptom interference with daily function 
(activity and affective subdimensions), 
symptom severity, overall symptom burden, 
self-efficacy, mood
Paper and pencil 
questionnaires: MDASI, 
SES6G, LASA Mood Scale
Four measurements over 
16 weeks: from BL to t3
Adoption
(Organisational)
Characteristics of participating centre and 
staff, usual support for SSM, facilitators 
and barriers for SN©P adoption
Focus group interviews (1), 
electronic questionnaires
Study start: before patient 
recruitment starts
Implementation
(Organisational)
(1) Acceptance and appropriateness of 
nurses’ trainings: training content, nurses’ 
confidence to integrate SN©P into practice, 
work-related factors with implementing 
SN©P
Paper and pencil 
questionnaire,
Work-SoC scale
After first and second 
training
(2) Nurses’ and physicians’ acceptance of 
SN©P
Focus group interviews (2) 
and telephone interviews
After patients completed all 
questionnaires (last patient 
out of study)
(3) Nurses’ fidelity to training manual: 
key elements applied, patients’ complaints 
and goals, number and topic of delivered 
SN©Fyers, additionally delivered 
information leaflets
Electronic questionnaires
Observations
After every semistructured 
consultations
(4) Patients’ safety Electronic questionnaires
Focus group interviews (2)
After semistructured 
consultations
(5) Resources: time needed for trainings, 
preparing and providing nurse-led 
consultations, documentation
Training logs
Electronic questionnaires
After training courses 
and after semistructured 
consultations
(6) Quality of nursing care estimated by 
patients
PR-CISE (paper and pencil 
questionnaires)
Three measurements: t1–t3
Maintenance Not applied Not applied Not applied
Focus group interviews (1): takes place before patient recruitment starts at the centre; Focus group interviews (2): takes place after last 
patient is out of study. 
 BL, baseline; MDASI, MD Anderson Symptom Inventory; PR-CISE, patient-reported chemotherapy indicators of symptoms and experiences; 
RE-AIM, Reach Effectiveness—Adoption Implementation Maintenance; SES6G, Self-Efficacy for Managing Chronic Disease Questionnaire; 
SSM: Symptom Self-Management; SN©P: Symptom Navi© Program; SN©Flyers: Symptom Navi© Flyers (written information leaflets for 
patients); Work-SoC, Work-related Sense of Coherence scale. 
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Adoption
We will assess the characteristics of participating outpa-
tient cancer centres and nurses (ie, specialised cancer 
centre, nurses’ formation, number of employed nurses 
and oncologists at each intervention centre, average 
number of delivered anticancer treatments per day, 
number of treated patients at the centre per year, infor-
mation leaflets usually delivered to patients).
We will conduct a first focus group interview with nurses 
before they will be trained for the SN©P to learn about the 
current symptom self-management support and handling of 
written information at each intervention centre. A second 
focus group interview (after last patient is out of study at the 
centre) will be conducted with those nurses who provided 
the intervention to assess perceived barriers and facilitators 
(eg, work-related factors, available resources) for adopting 
the SN©P within daily routines (figure 1).
Interview guidelines for semistructured focus groups 
will be based on Morgan.58
Implementation
To evaluate the success of the implementation we will 
assess:
1. Acceptance and appropriateness of the nurse-training 
course by using a 5-item paper and pencil question-
naire based on the training manual. We developed 
five questions regarding content and acceptability us-
ing 7-point Likert scales rated from 1 (not at all) to 
7 (greatest possible). Two open-ended questions for 
narrative feedback on both training courses comple-
ment the Likert scales. To assess potentially influenc-
ing work-related factors for implementing the SN©P 
into practice, we added the Work-related Sense of 
Coherence (Work-SoC) scale.59 The Work-SoC scale 
is a 9-item validated screening instrument for assess-
ing employees’ perceived quality of work situation on 
three subscales: comprehensibility, manageability and 
meaningfulness.59
2. Acceptance and feasibility of the SN©P within daily 
routines will be explored using focus group interviews 
with nurses and a telephone interview with one oncol-
ogist from each of the intervention centres. Interviews 
with oncologists were included to represent the insti-
tutions voice regarding acceptance and feasibility of 
the SN©P within daily routines. Focus group and tele-
Figure 1 Study flowchart for the Symptom Navi© Pilot Study with included patient timeline. *Every patient enrolled for the 
pilot study will start with SN©P and will be followed by two semistructured nurse-led consultations. **Semistructured nurse-led 
consultations take place during first and second scheduled treatment application at the outpatient centres of the intervention 
arm. BL, baseline.
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phone interviews will be directed by semistructured in-
terview guidelines.58 60 Topics addressed in both inter-
views will focus on symptom self-management support 
based on the frameworks of Howell et al13 and Schof-
ield and Chambers.15
3. Nurses report on fidelity to the training manual by us-
ing electronic questionnaires. These questionnaires 
were developed based on the six key elements of sem-
istructured consultations. Sixteen questions are in 
dichotomous format (yes–no); three text fields are 
added for reporting patients’ complaints, their goals 
regarding symptom self-management behaviours, and 
observed ‘unsafe’ behaviour of patients. We consider 
as unsafe behaviour, for example, a delayed reaction 
of a patient despite severe symptoms such as fever with 
neutropenia or exacerbated diarrhoea. In addition, a 
study team member will observe two semistructured 
consultations at each centre by using the above-men-
tioned questionnaire in printed format to record ob-
served behaviour of nurses.
4. Patients’ safety will be also explored with focus group 
interviews with nurses and telephone interviews with 
oncologists. Serious adverse events will be assessed 
electronically according to authority guidelines.61 62
5. Resources needed to implement the SN©P at the cen-
tres will be assessed based on training duration and 
number of participating nurses documented on train-
ing logs. Nurses will assess electronically time needed 
for semistructured consultations including prepara-
tion and documentation of consultations.
6. Quality of nursing care evaluated by patients will assess 
five concerns: do nurses ask patients about symptoms, 
provide useful information, and/or practical advice to 
manage symptoms, are they aware of patient’s symp-
tom severity, and whether patients feel confident to 
manage symptoms. The patient-reported chemotherapy in-
dicators of symptoms and experiences (PR-CISE)28 is a qual-
ity measure for outpatient chemotherapy settings. We 
translated five items of the original PR-CISE question-
naire following a forward and backward translation 
process based on a translation and cultural adaptation 
guideline.63 The translation was reviewed by two nurs-
ing experts and pilot-tested with 10 cancer patients 
from an outpatient cancer centre that will not partici-
pate in this study.
sample size and randomisation
We aim to include a total of 140 patients in 9 clusters—
with ~70 patients to be included in both the intervention 
and the control group, and about 10–20 patients in each 
cluster (at each centre).
Due to the lack of data on the expected magnitude of 
effect of SN©P on outcomes, we did not formally calcu-
late a sample size,44 but rather estimated the power for 
the expected sample size. Assuming an intraclass correla-
tion of 0.05, a type I error rate of 5% and an equal distri-
bution of the patients among the clusters, a total sample 
size of 135 patients (ie, 9 clusters with 15 patients) would 
allow a detection of an effect size of 0.5, 0.75 and 1 with 
powers of about 60%, 91% and 99%, respectively, based on 
a two-sample comparison of means in a cluster-randomised 
design.
The Clinical Trial Unit of the University of Bern (CTU 
Bern) will execute the randomisation at the level of cancer 
outpatient centres. Randomisation will be stratified by the 
expected recruitment potential (fast vs slow recruiters) and 
will be based on randomly permuted blocks with a block size 
of two to minimise potential imbalances within the small 
number of included clusters. We assume that nurses are 
more familiar with treatment protocols at faster recruiting 
centres, and therefore might also be more experienced with 
supporting patients during anticancer treatments. Stratifi-
cation will also help with balancing the number of patients 
between treatment groups since cluster size depends on the 
recruitment potential. We will not implement allocation 
concealment or blinding procedures.
data collection and management
A data capturing system (secuTrial) will be set up for data 
entry at CTU Bern for all quantitative data. Nurses and 
physicians involved with the study procedures will have 
a personal login to secuTrial for data recording. A dedi-
cated nurse and a principal investigator (an oncologist 
who has worked for at least 1 year at the centre) at each 
centre will be responsible for identifying eligible patients 
for study inclusion and informing patients orally and in 
written format about the study.
The study procedure is summarised in a participants’ 
flowchart (see figure 1). The BL assessment will take place 
before patients start their first treatment application at 
the outpatient cancer centre. Two further assessments will 
take place between subsequent treatment applications (t1 
between second and third, t2 between third and fourth 
treatment application) when the patient is at home. This 
takes into account the variety of treatment protocols with 
different administration schedules. The last assessment 
(t3) will again be completed by the patient at home, 16 
weeks (±1 week) after the BL assessment.
Nurses will hand over questionnaires and prestamped 
addressed envelopes to patients and inform them when 
they should fill in the questionnaire at home. Returned 
questionnaires will be entered centrally into secuTrial by 
a study team member. After every semistructured consul-
tation with a patient, nurses will complete an electronic 
questionnaire assessing their fidelity to the training 
manual, and patient’s complaints and goals for symptom 
self-management as discussed during the consultation.
All focus group interviews will be audio recorded and 
transcribed. After patient recruitment is completed at an 
intervention centre, a telephone interview with one oncolo-
gist will be conducted. Data management of qualitative data 
will be based on excel sheets and logbooks, if applicable.
Patient recruitment started in November 2017. We 
expect the last patient to complete the study by the end 
of April 2019 and to complete the qualitative data assess-
ment by the end of June 2019.
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Analysis
The null hypothesis, that there is no difference in the 
changes of symptom interference score of the MDASI 
between intervention and control group, will be tested 
against a two-sided alternative. We will perform a primary 
analysis on the intention-to-treat population (ie, analysing 
all patients according to the intervention they were 
assigned to at randomisation) and a secondary analysis on 
the perprotocol population (ie, excluding patients who 
were not treated according to protocol). All effectiveness 
outcomes will be analysed using linear or generalised linear 
mixed-effects models. BL measurement, treatment group, 
time point (ie, t1, t2 or t3) and the interaction of group 
and time point will be included as fixed covariates, cluster 
and patient as nested random effects. We will present all 
results using an effect measure with a two-sided 95% CI and 
a p value. In a sensitivity analysis, we will adjust the model 
for potential confounders, that is, patient, nurse or cluster 
characteristics that show imbalances at BL.
All other outcomes will be analysed descriptively. A 
statistical analysis plan with a detailed description of data 
preparation and analysis will be written in collaboration 
with a statistician before completion of recruitment. 
Quantitative analysis will be performed in collaboration 
with the CTU in Bern using an appropriate statistical soft-
ware (eg, R 3.6.0 or STATA 14.2).
Transcripts of focus group and individual interviews, as 
well as narrative information from the questionnaires on 
fidelity including patients’ goals for symptom self-man-
agement will be analysed by thematic analysis.64 Thematic 
analysis is a six-phase approach to identify patterns 
(themes): (1) familiarising with data, (2) generating initial 
codes, (3) searching for themes, (4) reviewing themes, 
(5) defining and naming themes and (6) producing the 
report.64 Transcripts will be coded independently by two 
members of the research team. A third member will be 
involved to discuss discordances between the two coders 
until consensus is reached.
Patient and public involvement
We did not involve patients or public for developing this 
pilot study. Results of the study will be presented at each 
participating cancer outpatient centre. An assessment of 
patients’ burden of the intervention was not included in 
the pilot study based on previous evaluation of the inter-
vention from patients’ perspective confirming that the 
SN©P did not cause burden for patients.
EthICs And dIssEMInAtIon
This pilot study has been reviewed by four Swiss Ethics 
Committees and approved by the Swiss Ethic Committee 
in Bern (KEK-BE: 2017–00020), and will be conducted 
in accordance to the Declaration of Helsinki65 and the 
International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use/
Good Clinical Practice (ICH-GCP) guidelines.66 Any modi-
fication of the protocol will be submitted to and approved 
by the leading Ethic Committee in Bern. Patients will sign 
a written informed consent form (online supplemen-
tary file 1) before being included in the study. Signed 
informed consent forms and patient enrolment logs will 
be stored at the outpatient cancer centres. All data will 
be anonymised when presented at scientific meetings or 
published. Serious adverse events will be assessed by local 
principal investigators and evaluated according standard 
serious adverse reporting procedures.67 We registered this 
pilot study at  ClinicalTrials. gov and at the Swiss National 
Clinical Trials Portal (SNCTP): SNCTP000002381.
Results of this study will be disseminated at national 
and international conferences and published in peer-re-
viewed journals with a preference of open access jour-
nals. Nurses at the control group centres will be trained 
on the SN©P to implement it at their centre after pilot 
study completion and confirmation that the SN©P can 
be considered to be safe. If the safety of the SN©P will 
be confirmed with this study, we plan to collaborate with 
the Swiss Cancer League for broader dissemination of 
the SN©P in Switzerland. Supporting self-management 
strategies of cancer patients is an explicit aim of the Swiss 
National Strategy against Cancer.68 69
dIsCussIon
The Symptom Navi© Pilot Study aims to evaluate the 
implementation of the SN©P within daily routines. We will 
evaluate preliminary effectiveness and safety of the inter-
vention on patient-reported interference of symptoms with 
daily functions, symptom intensity and burden, perceived 
self-efficacy and quality of nursing care. The results may 
contribute to greater insight into the mediating role of 
self-efficacy for self-management of symptoms.51 We expect 
the SN©P to enhance nurse-led support for cancer patients 
in the outpatient setting. Estimated effect sizes will serve 
for effect and sample size calculations for a fully powered 
cluster randomised controlled clinical trial.
Successful implementation of complex interventions 
depends on providing the intervention as intended, but 
also on contextual factors.32 39 To meet these challenges, 
we have designed a study based on the RE-AIM frame-
work using a cluster-randomised design complemented 
with qualitative methods.70 The SN©P has been thor-
oughly developed49 and patients confirmed that they 
could improve their self-management behaviours by 
using SN©Flyers.71 Therefore, the SN©P is a promising 
nurse-led intervention to support patients’ symptom 
self-management and enrich current usual care practices 
in the outpatient cancer setting, but its implementation 
and effectiveness need to be investigated.
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